Q-omics provides the consensus-scored TRPT1 profile across patient tissues and cancer cell-line models. TRPT1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TRPT1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TRPT1 RNA expression shows 18,261 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, KIRC, and THYM as cancer lineages where TRPT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPT1 survival associations across molecular data types. TRPT1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPT1 RNA expression–survival associations across cancer types. High TRPT1 expression shows unfavorable associations in KICH, ACC and KIRC, but favorable associations in MESO, CHOL and BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for TRPT1 RNA expression.
This table summarizes TRPT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRPT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPT1 shows higher tumor expression in KIRC, BLCA, LUSC, LUAD, LIHC and UCEC. The KIRC box plot shows higher TRPT1 RNA expression in tumor versus normal tissue (log2 FC = +0.475, t-test p < 0.001).
This table shows molecular features associated with TRPT1 in patient tissues and cancer cell lines. In patient samples, TRPT1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
